在青少年异常性关节炎中不耐受口服甲状腺素
Ai Yuda1,2, Tomo Nozawa1, Seira Hattori1
1Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.
概括
口服甲状腺素 (MTX) 是一种常见的治疗青少年异常性关节炎 (JIA). 然而,许多JIA患者经历了恶心和吐等不良事件,影响了治疗的成功和坚持.
科学领域:
- 儿科风湿病学 儿科风湿病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 口服甲状腺素 (MTX) 是青少年异常性关节炎 (JIA) 的首要疗法.
- 不良事件 (AE),特别是恶心和吐,经常会损害JIA患者的MTX的坚持和疗效.
- 了解MTX不可容忍性对于优化JIA管理至关重要.
研究的目的:
- 评估青少年异常性关节炎 (JIA) 患者口服甲状腺素 (MTX) 不耐受性的发生率和影响.
- 在JIA中识别与MTX治疗相关的常见不良事件 (AE).
- 评估MTX不耐受性对治疗结果的影响,包括缓解和对生物药物的需要.
主要方法:
- 在2011年4月至2022年10月期间,对52名青少年异常性关节炎 (JIA) 患者进行了回顾性分析,这些患者接受了口服甲状腺素 (MTX) 治疗.
- 评估了对日本临床指南的剂量遵守 (目标10毫克/米2/周,最大16毫克/周).
- 记录了副作用的发生率,特定症状,对缓解的影响以及对生物制剂的需求.
主要成果:
- 68%的患者经历了副作用,恶心和吐是最常见的 (42%在6个月内,67%在12个月内).
- 29%的患者由于AE无法耐受目标MTX剂量.
- 由于MTX相关的恶心/吐,21%的患者未能达到或维持缓解,其中17%需要生物药物.
结论:
- 口服甲状腺素 (MTX) 不耐受性是青少年异常性关节炎 (JIA) 的一个重要问题,影响了近三分之二的患者.
- 恶心和吐是常见的副作用,可能导致治疗失败,缓解失败和升级到生物疗法.
- MTX不耐受性对治疗结果产生重大影响,需要在JIA中仔细监测和管理策略.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
210
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
210
01:29Inflammatory Bowel Disease IV: Pharmacological Management
204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
204
01:07Teratogenicity
2.8K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.8K
01:17Phase II Reactions: Methylation Reactions
370
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
370